Akcea Therapeutics Inc 's ROA from the second quarter of 2020 to the second quarter of 2019 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Akcea Therapeutics Inc 's ROA in the second quarter of 2020?
Akcea Therapeutics Inc recorded a cumulative net loss of $-42 million during 12 months ending in the second quarter of 2020, resulting in a negative return on assets (ROA) of -8.1%.

However, within the Healthcare sector 260 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2020 from 3199 to 3230.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2020) II. Quarter	(Mar 31 2020) I. Quarter	(Dec 31 2019) IV. Quarter	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter
Y / Y Total Assets Change	19.37 %	22.06 %	-11.81 %	4.39 %	12.73 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-42	-29	41	-112	-144
Return On Assets (TTM)	-8.1 %	-5.95 %	8.74 %	-23.08 %	-29.93 %
AKCA's Total Ranking	# 3230	# 3199	# 768	# 3968	# 4125
Total Assets (TTM) in million	518	560	589	383	434
Seq. Total Assets Change	-7.45 %	-4.97 %	53.78 %	-11.74 %	-5.36 %
Seq. Net Income Change	-	-	-	-	-

AKCA's 5 Years Annual ROA >> Back to AKCA Management Effectiveness >> Compare AKCA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 84
Sector	# 261
Overall	# 3123

Return On Assets Statistics
High	Average	Low
8.7 %	-35.33 %	-70.17 %
(Dec 31 2019)		(Dec 31 2017)

Financial Statements
Akcea Therapeutics Inc 's Assets	$ 518 million	AKCA's Balance sheet
Akcea Therapeutics Inc 's Income	$ -50 million	Quarterly AKCA's Income Statement
AKCA's Income by Division		See AKCA's Income by Division

Annual Return On Assets	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2015) FY 2017	FY	FY
Y / Y Total Assets Change	-10.31 %	595.15 %	-	-	-
Total Assets in million	599	668	96	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	41	-226	-61	0	0
Annual Return On Assets	6.8 %	-33.8 %	-63.9 %	-	-

AKCA's 5 Years Annual ROA >> Back to AKCA Management Effectiveness >> Compare AKCA ROA to its Competitors

Comment on AKCA's ROA in the fiscal year ending 2019

In the fiscal year 2019 ROA improved to 6.8 % compared to prior year, due to annual net income growth of % to $40.77 million, and due to decline of value in Akcea Therapeutics Inc 's assets by -10.31 % to $599.25 million, compared to $599.25 a year before.

More Return On Assets Ratios
AKCA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AKCA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AKCA's Competitors
Subscribers only: Roa for Akcea Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for AKCA's Customers

You may also want to know
AKCA's Roi	AKCA's Inventory Turnover Ratio	AKCA's Growth Rates	AKCA's Dividend Comparisons
	AKCA's Profitability Ratios	AKCA's Asset Turnover Ratio	AKCA's Dividend Growth
AKCA's Roe	AKCA's Valuation Ratios	AKCA's Financial Strength Ratios	AKCA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2020, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:40:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.